The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rubanenko M.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Manturova N.E.

Pirogov Russian National Research Medical University;
Institute of Plastic Surgery and Cosmetology

Ustyugov A.Yu.

The Russian National Research Medical University named after N.I. Pirogov

Porshina O.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology

Petunina V.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Zorin V.L.

Human Stem Cells Institute PJSC, Skincel LLC (Skolkovo)

Zorina A.I.

Human Stem Cells Institute PJSC, Skincel LLC (Skolkovo)

Palinkash A.M.

Children‘s City Clinical Hospital named after G.N. Speransky

Epidermolysis bullosa. Possible methods of treatment

Authors:

Rubanenko M.V., Manturova N.E., Ustyugov A.Yu., Porshina O.V., Petunina V.V., Zorin V.L., Zorina A.I., Palinkash A.M.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2021;20(4): 22‑32

DOI: 10.17116/klinderma20212004122

Views: 2217

Downloaded: 89

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Rubanenko MV, Manturova NE, Ustyugov AYu, et al. . Epidermolysis bullosa. Possible methods of treatment. Russian Journal of Clinical Dermatology and Venereology. 2021;20(4):22‑32. (In Russ.)
https://doi.org/10.17116/klinderma20212004122

 
МСФ на ЯМ
Close metadata
Recommended articles:
Features of gene­ral anesthesia during dental inte­rventions in children with dystrophic epidermolysis bullosa. Stomatology. 2025;(1):63-70

More than 6.000 orphan (rare) diseases have been described in the world. Most of them are caused by genetic disorders and accompany a person throughout his life. These are pathologies characterized by a severe debilitating course and in most cases without etiology-pathogenesis treatment so, the urgent task of world health is to develop methods for effective treatment of these diseases. Therefore, since the 2000s a promising direction for the treatment of orphan diseases is the use of innovative approaches based on cell and gene therapy. «Research successes and technological solutions in the field of cellular technologies may be so significant that they can be classified as critical» (M.A. Paltsev, 2014). The article presents statistical data on orphan diseases and current approaches to treatment based on the development of biomedical cell products on the example of recessive dystrophic epidermolysis bullosa. The term «hereditary epidermolysis bullosa» was first used in 1886 to describe a genetically determined disease characterized by the exceptional trauma of the skin with subsequent formation of blisters and erosions. Cell therapy for patients with this disease consists in intradermal injection into the lesions of a biological product — cells that can replace the function of cells with a genetic mutation. Clinical results make it possible to evaluate the technique of using cell therapy as promising for the restoration of the skin integrity in recessive dystrophic epidermolysis bullosa.

Keywords:

orphan diseases
epidermolysis bullosa
genetic pathology
biomedical cell products

Authors:

Rubanenko M.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Manturova N.E.

Pirogov Russian National Research Medical University;
Institute of Plastic Surgery and Cosmetology

Ustyugov A.Yu.

The Russian National Research Medical University named after N.I. Pirogov

Porshina O.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology

Petunina V.V.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology;
The Russian National Research Medical University named after N.I. Pirogov

Zorin V.L.

Human Stem Cells Institute PJSC, Skincel LLC (Skolkovo)

Zorina A.I.

Human Stem Cells Institute PJSC, Skincel LLC (Skolkovo)

Palinkash A.M.

Children‘s City Clinical Hospital named after G.N. Speransky

Received:

05.04.2021

Accepted:

08.06.2021

List of references:

  1. Rachinskaya OA, Vodyakova MA, Melnikova EV, Merkulov VA. Treatment of Genetic Diseases: Current Trends in the Development of Biomedical Cell Products. BIOpreparations. Prevention, Diagnosis, Treatment. 2019;19(4): 225-231. (In Russ.).
  2. Belousov YuB. Bolezni-siroty i sirotskie lekarstva. Remedium. 2007;9:8-10. (In Russ.).
  3. Rare Diseases: understanding this public health priority [Electronic resource] European Organisation for Rare Diseases. 2005. https://archive. eurordis.org/article.php3? id_article=918/
  4. Orphan Drug Act of 1983. US Food and Drug Administration. 4 January 1983. 2015.
  5. Rare disease. Accessed Mar 03, 2021. (In Russ.). https://rare-diseases.ru/rare-diseases
  6. Nguengang S, Lambert D, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. European Journal of Human Genetics. 2019;28:165-173. 
  7. Federal’nyi zakon Rossiiskoi Federatsii ot 21.11.11 N 323-FZ «Ob osnovakh okhrany zdorov’ya grazhdan v Rossiiskoi FederatsiI». (In Russ.).
  8. Perechen’ redkikh (orfannykh) zabolevanii. Minzdrav Rossii. (In Russ.). https://www.rosminzdrav.ru/documents/8048-perechen-redkih-orfannyh-zabolevaniy
  9. The portal of rare diseases. Accessed Mar 03, 2021 (In Russ.). https://www.who.int/medicines/areas/priority_medicines/Ch6_19Rare.pdf?ua=1
  10. The portal for rare diseases and orphan drugs. Accessed Mar 03, 2021. (In Russ.). https://www.orpha.net
  11. Vitkovskaya IP. Sovershenstvovanie organizatsii meditsinskoi pomoshchi detyam s orfannymi zabolevaniyami v Moskve. M. 2019. (In Russ.).
  12. Chicherin LP, Prokofyeva YA. Modern problems of orphan diseases. Byulleten’ Natsional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya im. N.A. Semashko. 2019;1:118-124. (In Russ.).
  13. Shved AD, Tourovets AN. Epidermolysis bullosa: approaches of gene and cell therapy. Kletochnaya transplantologiya i tkanevaya inzheneriya. 2011; VI(4):21-25. (In Russ.).
  14. Novikov PV. Legal issues relating to rare (orphan) diseases — Russian and international experience. Meditsina. 2013;4:53-73. (In Russ.).
  15. Lee JYW, Liu L, Hsu CK, et al. Mutations in KLHL24 add to the molecular heterogeneity of epidermolysis bullosa simplex. J Invest Dermatol. 2017; 137(6):1378-1380.
  16. Bruckner-Tuderman L, McGrath J, Robinson E, Uitto J. Progress in epidermolysis bullosa research: summary of DEBRA International Research Conference 2012. J Invest Dermatol. 2013;133(9):2121-2126.
  17. Kubanov AA, Albanova VI, Chikin VV, Yepishev RV. Modern methods of the treatment of hereditary epidermolysis bullosa. Vestnik Dermatologii i Venerologii. 2014;6:47-56. (In Russ.).
  18. Fine J, Bruckner-Tuderman L, Eady R, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103-1126.
  19. Fine J. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:12. 
  20. Soro L, Bartus C, Purcell S. Recessive dystrophic epidermolysis bullosa a review of disease pathogenesis and update on future therapies. J Clin Aesthet Dermatol. 2015;8(5):41-46. 
  21. Federal’nye klinicheskie rekomendatsii povedeniyu bol’nykh vrozhdennym bulleznym ehpidermolizom. Rossiiskoe obshchestvo dermatovenerologov i kosmetologov. 2015. (In Russ.). https://www.pediatrrussia.ru/sites/default/files/file/kr_vbe.pdf
  22. Vanden Oever M, Twaroski K, Osborn MJ. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa. Pediatric RESEARCH. 2017.
  23. Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res. 2017;6(1):6-20. 
  24. Varki R, Sadowski S, Uitto J, et al. Epidermolysis bullosa. II.Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. J Med Genet. 2007;44:181-192. 
  25. Zorina AI, Zorin VL, Kopnin PB, Treatment of epidermolysis bullosa and aesthetic correction of its manifestations using cellular technologies. In»ektsionnye metody i protsedury. 2018;2:105-113. (In Russ.).
  26. Shinkuma S. Dystrophic epidermolysis bullosa:review. Clinical, Cosmetic and Investigation Dermatology. 2015; 8:275-284. 
  27. Mittapalli VR, Madl J, Loffek S, Kiritsi D, Kern JS, Romer W, et al. Injury-Driven Stiffening of the Dermis Expedites Skin Carcinoma Progression. Cancer Res. 2016;76(4):940-951. 
  28. Bobko SI, Albanova VI. Problems of physical development of patients with bullous epidermolysis. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2011;5:42-43. (In Russ.).
  29. Jeon IK, On HR, Kim SC. Quality of life and economic burden in recessive dystrophic epidermolysis bullosa. Ann Dermatol. 2016;28:6-14. 
  30. Mellerio JE, Robertson SJ, Bernardis C, et al. Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. Br J Dermatol. 2016;174:56-67. 
  31. Zakharova NI, Yanin VA, Krikunova VL, Khlebushkina VM, Gavrilova OS. Dystrophic type ofautosomal dominant bullous epi-dermolysis ina newborn. Ros Vestn Perinatol i Pediatr. 2019;64(3):78-81. (In Russ.). https://doi.org/10.21508/1027-4065-2019-64-3-78-81
  32. Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res. 2017;6(1):6-20.  https://doi.org/10.5582/irdr.2017.01005
  33. Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2008;128:2179-2189.
  34. Petrof G, Martinez-Quiepo M, Mellerio J, et al. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial. Br J Dermatol. 2013;169(5): 1025-1033.
  35. Venugopal SS, Yan W, Frew JW, et al. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2013;69:898-908. 
  36. Tolar J, Wagner J. Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Lancet. 2013;382:1214-1223.
  37. Wagner J, Ishida-Yamamoto A, McGrath J, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010; 363:629-639. 
  38. Conget P, Rodriguez F, Kramer S, et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 2010;12(3):429-431. 
  39. Kletochnaya transplantologiya i tkanevaya inzheneriya: Nauchno-informatsionnyi i analiticheskii zhurnal. 2009;4(3):84. (In Russ.).
  40. Osborn M., Newby G, McElroy A, et al. Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. The Journal of Investigative Dermatology. 2019;140(2):338-347. 
  41. Latella MC, Cocchiarella F, De Rosa L, Turchiano G, Goncalves M, Larcher F, et al. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes. J Invest Dermatol. 2017;137(4):836-844. 
  42. Kemp P. History of regenerative medicine: looking backwards to move forwards. Med. 2006;1(5):653-669. 
  43. Sorrell M, Caplan AI. Fibroblasts — a diverse population at the center of it all. Int Rev Cell Mol Biol. 2009;276:161-214. 
  44. Weiss RA, Weiss MA, Beasley KL, Munavalli G. Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol Surg. 2007;33(3):263-268. 
  45. Zorina AI, Zorin VL, Cherkasov VR, Isaev AA. A method for correction of age-related skin changes by using autologous dermal fibroblasts. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2013;3:30-37. (In Russ.).
  46. Phillips T, Gilchrest B. Cultured epidermal allograft as biological wound dressings. Prog Clin Biol Res. 1991;365:77-94. 
  47. Woodley D, Hou Y, Martin S, Chen M. Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using sitedirected mutagenesis. J Biol Chem. 2008;283(26):17838-17845.
  48. Fritsch A, Loeckermann S, Kern J, et al. A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest. 2008;118(5):1669-1679.
  49. Wong T, Gammon L, Liu L, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2008;128(9):2179-2189.53, 54. 
  50. Nagy N, Almaani N, Tanaka A. HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2011;131(8):1771-1774.
  51. Kern J, Loeckermann S, Fritsch A, et al. Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: High stability of collagen VII favors long-term skin integrity. Mol Ther. 2009;17(9):1605-1615.
  52. Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, et al. Amelioration of Epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood. 2009;113:1167-1174.
  53. Tamai K, Yamazaki T, Chino T, Ishii M, Otsuru S, Kikuchi Y, et al. PDGFRα-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA. 2011; 108:6609-6614.
  54. Liao Y, Ivanova L, Sivalenka R et al. Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model. Stem cells translational medicine. 2018;7:530-542. 
  55. Cairo MS, Tarek N, Lee DA, et al. Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients. Bone Marrow Transplant. 2016;51:27:2120.
  56. Robin C, Bollerot K, Mendes S et al. Human placenta is a potent hematopoietic niche containing hematopoietic stem and progenitor cells throughout development. Cell Stem Cell. 2009;5:385. 
  57. Barcena A, Kapidzic M, Muench MO, et al. The human placenta is a hematopoietic organ during the embryonic and fetal periods of development. Dev Biol. 2009;327:24. 
  58. Conget P, Rodriguez F, Kramer S, et al. Replenishment of type VII collagen and reepithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy. 2010;12(3):429-431. 
  59. El-Darouti M, Fawzy M, Amin I. Treatment dystrophic epidermolysis bullosa with bone marrow non-hematopoietic stem cells: a randomized controlled trial. Dermatol Ther. 2016;29(2):96-100. 58, 59. 
  60. Pittenger M, Mackay A, Beck S, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147. 
  61. Kumar PL, Kandoi S, Misra R, Vijayalakshmi S, Rajagopal K, Verma RS. The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46:1-9. 
  62. Caplan A, Dennis E. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076-1084.
  63. Sasaki M, Abe R, Fujita Y, et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol. 2008;180(4):2581-2587.
  64. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007; 25(10):2648-2659.
  65. Galderisi U, Giordano A. The gap between the physiological and therapeutic roles of mesenchymal stem cells. Med Res Rev. 2014;34(5):1100-1126.
  66. Boink M, van den Broek L, Roffel S, et al. Different wound healing properties of dermis, adipose, and gingiva mesenchymal stromal cells. Wound Repair Regen. 2016;24(1):100-109.  https://doi.org/10.1111/wrr.12380
  67. Wang Y, Chen X, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15(11):1009-1016.
  68. Nauta A, Fibbe W. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499-3506.
  69. Maxson S, Lopez E, Yoo D. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med. 2012;1:142-149. 
  70. El-Darouti M, Fawzy M, Amin I. Treatment dystrophic epidermolysis bullosa with bone marrow non-hematopoietic stem cells: a randomized controlled trial. Dermatol Ther. 2016;29(2):96-100. 
  71. Petrof G, Lwin Su M, Martinez-Queipo M, et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2015;135(9):2319-2321.
  72. Rashidghamat E, Kadiyirire T, Ayis S, et al. Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2020;447-454. 
  73. Jonkman MF, Scheffer H, Stulp R, Pas HH, Nijenhuis M, Heeres K, et al. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell. 1997;88(4):543-551. 
  74. Hsu CK, Wang SP, Lee J Y-Y, McGrath J Y-Y. Treatment of hereditary epidermolysis bullosa: updates and future prospects. Am J Clin Dermatol. 2014; 15(1):1-6. 
  75. Beilin AK, Gurskaya NG, Vorotelyak EA. Methods of gene therspy for treatment of inherited epidermolysis bullosa. Vestn. Mosk. un-ta. Ser. 16. Biologiya. 2018;73(4):233-240. (In Russ.).
  76. Abdul-Wahab A, Qasim W, McGrath JA. Gene therapies for inherited skin disorders. Semin Cutan Med Surg. 2014;33(2):83-90. 
  77. Siprashvili Z, Nguyen N, Gorell E, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316(17):1808-1817.
  78. Bauer JW, Koller J, Murauer EM, et al. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells J Invest Dermatol. 2017;137(3):778-781. 
  79. Georgiadis C, Syed F, Petrova A, et al. Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. Journal of Investigative Dermatology. 2016;136:284-292.  https://doi.org/10.1038/JID.2015.364
  80. Lwin Su M, Syed F, Di Wei-Li, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4(11):126243. https://doi.org/10.1172/jci.insight.126243
  81. Goto M, Sawamura D, Ito K, et al. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa. J Invest Dermatol. 2006;126:766-772. 
  82. Titeux M, Pendaries V, Zanta-Boussif MA, et al. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa. Mol Ther. 2010;18:1509-1518.
  83. Woodley DT, Krueger GG, Jorgensen CM, et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol. 2003;121:1021-1028.
  84. Woodley DT, Remington J, Huang Y, et al. Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing. Mol Ther. 2007;15:628-635. 
  85. Lwin Su M, Syed F, Di Wei-Li, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4(11):126243. https://doi.org/10.1172/jci.insight.126243
  86. Wu W, Lu Z, Li F, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model. Proc Natl Acad Sci USA. 2017;114(7):1660-1665.
  87. Aushev M, Koller U. Traceless Targeting and Isolationof Gene-Edited Immortalized Keratinocytesfrom Epidermolysis Bullosa Simplex Patients, olecular Therapy: Methods & Clinical Development. 2017;6:112-123. 
  88. Osborn MJ, Starker CG, McElroy AN, et al. TALEN-based gene correction for epidermolysis bullosa Mol Ther. 2013;21:1151-1159.
  89. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007;2:3081-3089.
  90. Kim EJ, Kang KH, Ju JH. CRISPR-Cas9: A promising tool for gene editing on induced pluripotent stem cells. Korean J Intern Med. 32, 42-61. 
  91. Moreno AM, Mali P. Therapeutic genome engineering via CRISPR — Cas systems. Wiley Interdiscip. Rev Syst Biol Med. 2017;9:1380.
  92. Shinkuma S, Guo Z, Christiano AM. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Proc Natl Acad Sci USA. 2016;113:5676-5681.
  93. Jackówa J, Guoa Z, Hansena C, et al. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells. PNAS. 2019;116(52):26846-26852.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.